BioPorto A/S
THOXF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.97 | 0.61 | -1.97 | 0.83 |
| FCF Yield | -9.97% | -5.28% | -3.72% | -4.95% |
| EV / EBITDA | -11.19 | -17.13 | -17.69 | -21.82 |
| Quality | ||||
| ROIC | -88.42% | -83.51% | -90.89% | -98.45% |
| Gross Margin | 67.68% | 65.19% | 65.73% | 62.01% |
| Cash Conversion Ratio | 1.11 | 0.98 | 0.64 | 0.99 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.75% | 8.48% | 7.68% | -3.06% |
| Free Cash Flow Growth | -51.24% | -4.79% | 18.49% | -75.04% |
| Safety | ||||
| Net Debt / EBITDA | 0.68 | 1.02 | 0.93 | 0.55 |
| Interest Coverage | -166.56 | -107.13 | -72.56 | -71.55 |
| Efficiency | ||||
| Inventory Turnover | 2.52 | 2.85 | 3.88 | 3.39 |
| Cash Conversion Cycle | 63.01 | -66.63 | -254.79 | 46.92 |